The FDA granted 510(k) clearance to Masimo (NSDQ:MASI) for its Rainbow acoustic monitoring sensor for use in children.
Previously cleared for adults, the device can now be used in the U.S. to monitor the respiration rate of pediatric patients.
The Rainbow uses an acoustic transducer that is taped to the patient’s neck. Masimo is championing the device as a better-tolerated option than capnography, which involves a nasal tube for monitoring.
“It’s going to be a home run. Kids don’t tolerate capnography," said Michael Ramsay, chief of anesthesiology at Baylor University Medical Center, according to a press release.
Irvine, Calif.-based Masimo recently posted strong 1st quarter results.